SOURCE: Mauna Kea Technologies

Mauna Kea Technologies

June 28, 2012 11:45 ET

Mauna Kea Technologies Announces Results of 2012 Annual Shareholders Meeting

PARIS--(Marketwire - Jun 28, 2012) - Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the endomicroscopy market, today announced the results of its 2012 Annual Meeting of Shareholders, which was held on June 15 in Paris with a quorum of 55% of shareholders present.

All resolutions supported by management were approved with over 90% of shareholders voting in favor.

In particular, the following resolutions were approved:

  • The election of Mr. Gilles Brisson as a director of the Board of Directors for a term of two years, until the 2014 Annual Meeting of Shareholders. Mr. Gilles Brisson is an independent board member and is also Chairman of the Board of Directors.

  • The election of Marie-Laure Pochon as a new director for a three-year term, until the 2015 Annual Meeting of Shareholders. Mrs. Pochon has been designated by Creadev to fill its second seat on the Board following the resignation of Mr. Nicholas Mulliez in March 2012.

Shareholders also approved the company's consolidated financial statements for the year ended December 31, 2011.

For additional details, Mauna Kea Technologies invites its shareholders to refer to the minutes of the Annual Shareholders Meeting, available on investor section of the company's website (in French) http://www.maunakea-corp.com/images/stories/PV_AGM_15_06_2012.pdf

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and help detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies, go to www.maunakeatech.com

Contact Information